Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 212,527 | 196,830 | 199,685 | 172,325 | 146,377 |
| Cost of Goods | 40,857 | 33,557 | 23,100 | 20,209 | 19,912 |
| Gross Profit | 171,670 | 163,273 | 176,585 | 152,116 | 126,465 |
| Operating Expenses | 198,693 | 211,110 | 206,128 | 214,415 | 211,894 |
| Operating Income | -26,166 | -47,280 | -29,443 | -62,090 | -84,517 |
| Interest Expense | 11,533 | 12,532 | 9,359 | 6,967 | 7,401 |
| Other Income | 1,632 | 2,959 | 1,259 | 2,804 | 4,765 |
| Pre-tax Income | -36,067 | -56,853 | -37,543 | -66,253 | -87,153 |
| Income Tax | 286 | 592 | 114 | 170 | 1,423 |
| Net Income Continuous | -36,353 | -57,445 | -37,657 | -66,423 | -88,576 |
| Net Income | $-36,353 | $-57,445 | $-37,657 | $-66,423 | $-88,576 |
| EPS Basic Total Ops | -0.30 | -0.46 | -0.30 | -0.54 | -0.70 |
| EPS Basic Continuous Ops | -0.29 | -0.46 | -0.30 | -0.54 | -0.70 |
| EPS Diluted Total Ops | -0.30 | -0.46 | -0.30 | -0.54 | -0.70 |
| EPS Diluted Continuous Ops | -0.29 | -0.46 | -0.30 | -0.54 | -0.70 |
| EPS Diluted Before Non-Recurring Items | -0.29 | -0.46 | -0.28 | N/A | N/A |
| EBITDA(a) | $-25,132 | $-55,101 | $-25,886 | $-55,504 | $-103,457 |